27
Participants
Start Date
June 14, 2017
Primary Completion Date
December 6, 2018
Study Completion Date
March 15, 2019
BAY1436032
"BAY1436032 administered continuously as a single agent dosed twice a day orally on Days 1 to 28 of a 28-day cycle.~Patients may continue treatment with BAY1436032 until disease progression, development of other unacceptable toxicity or Investigator discretion."
Mount Sinai Medical Center, New York
Universitätsklinikum Charite zu Berlin, Berlin
University of Pennsylvania, Philadelphia
Thomas Jefferson University, Philadelphia
Universitätsklinikum Hamburg Eppendorf (UKE), Hamburg
Wake Forest Baptist Health, Winston-Salem
Medizinische Hochschule Hannover (MHH), Hanover
Ohio State University, Columbus
Universitätsklinikum Heidelberg, Heidelberg
University of Texas MD Anderson Cancer Center, Houston
Roswell Park Comprehensive Cancer Center, Buffalo
Montefiore Medical Center, The Bronx
Universitätsklinikum Leipzig AöR, Leipzig
Lead Sponsor
Bayer
INDUSTRY